Wednesday, November 25, 2009, 12:51pm SGT - The Singapore stock market closes in 4 hours and 9 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Rigel Pharmaceuticals, Inc. (RIGL)

At 5:00AM SGT: 8.00 USD  Down 0.05 (0.62%)  
 MORE ON RIGL 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Rigel Pharmaceuticals, Inc. (NGM:RIGL) Delayed quote dataEdit
After Hours: 8.00 Down 0.00 (0.02%) as of 5:15am SGT on 11/25/09
Last Trade:8.00 USD
Trade Time:5:00AM SGT
Change:Down 0.05 (0.62%)
Prev Close:8.05
Open:8.05
Bid:7.07 x 100
Ask:8.88 x 100
1y Target Est:15.70
Day's Range:7.85 - 8.06
52wk Range:4.19 - 14.75
Volume:1,008,596
Avg Vol (3m):818,665
Market Cap:414.57M
P/E (ttm):N/A
EPS (ttm):-3.24
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add RIGL to Portfolio   Download Data

 HEADLINES 
•Rigel shares rise on RBC analyst upgrade
AP (Tue 1:53am)
•Rigel Pharms upgraded by RBC Capital Mkts
Briefing.com (Mon, Nov 23)
•Piper Jaffray Award Winning Analyst Says Health Care Reform Equity Valuation Fears Have Passed: Stock Picks For Q4 2009
Wall Street Transcript (Wed, Nov 11)
•Bristol Licenses Arthritis Drug: BioBuzz
at TheStreet.com (Tue, Nov 10)
•Biosimilars, Biologics, Biotech And Specialty Pharmaceuticals: Piper Jaffray Picks The Stocks And Sectors With Highest Potential Returns For Investors
Wall Street Transcript (Fri, Nov 6)
•RIGEL PHARMACEUTICALS INC Financials
EDGAR Online Financials (Fri, Nov 6)
•New Star Analyst Rankings for Rigel Pharmaceuticals, Inc.
StarMine (Wed, Nov 4)
•RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Wed, Nov 4)
•Rigel reports $26.7M loss in Q3
at bizjournals.com (Tue, Nov 3)
•UPDATE - Rigel to move arthritis drug forward; posts weak Q3
at Reuters (Tue, Nov 3)
More Headlines for RIGL...
 ANALYST 
EPS Est (next year) (Dec-09) :-2.72
EPS Est (in 2 years) (Dec-10) :-1.35
Avg Rec (current)*:1.8
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices